Sivik Global Healthcare LLC Lowers Stock Holdings in Cencora, Inc. $COR

Sivik Global Healthcare LLC trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 10.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,000 shares of the company’s stock after selling 2,000 shares during the quarter. Cencora accounts for approximately 1.8% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 11th biggest position. Sivik Global Healthcare LLC’s holdings in Cencora were worth $6,080,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Greenleaf Trust boosted its stake in shares of Cencora by 7.6% in the 4th quarter. Greenleaf Trust now owns 5,507 shares of the company’s stock valued at $1,860,000 after buying an additional 389 shares during the period. Palumbo Wealth Management LLC purchased a new position in shares of Cencora in the 4th quarter valued at about $215,000. Modera Wealth Management LLC boosted its stake in shares of Cencora by 11.8% in the 4th quarter. Modera Wealth Management LLC now owns 1,100 shares of the company’s stock valued at $371,000 after buying an additional 116 shares during the period. Raleigh Capital Management Inc. boosted its stake in shares of Cencora by 13.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 590 shares of the company’s stock valued at $199,000 after buying an additional 68 shares during the period. Finally, Landaas & Co. WI ADV purchased a new stake in Cencora during the fourth quarter worth approximately $208,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Wells Fargo & Company boosted their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Bank of America decreased their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Finally, Evercore reaffirmed an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $403.17.

Cencora Trading Down 0.1%

Shares of Cencora stock opened at $320.53 on Wednesday. Cencora, Inc. has a 1 year low of $269.37 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market capitalization of $62.35 billion, a P/E ratio of 38.53, a PEG ratio of 1.51 and a beta of 0.72. The company’s fifty day moving average is $347.21 and its two-hundred day moving average is $342.35.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the business earned $3.73 earnings per share. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. Analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is presently 28.85%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.